Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
ET in poster session II at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
- ET in poster session II at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
- A copy of the poster is available on the Zynerba corporate website at http://zynerba.com/publications/ .
- The poster titled, ZYN002 Cannabidiol Transdermal Gel: Efficacy and Safety Findings in Children and Adolescents With Autism Spectrum Disorder (ASD) and Related Disorders, shows that Zygel may provide important clinical promise across a spectrum of endpoints, including, behavior, seizure reduction and sleep.
- The data are from two open-label Phase 2 trials and one double-blind placebo-controlled trial when added to standard of care in children and adolescents.